Lusaris to develop psychedelic-based depression drug
2022-11-08
Backed by $60 million from a Series A funding round, Lusaris Therapeutics launched with the aim of advancing LSR-1019, a medication for treatment-resistant depression in a sublingual formulation of 5-MeO-DMT. Lusaris also entered into a strategic licensing collaboration with Catalent for the latter's Zydis fast-dissolving tablet technology that they will use for LSR-1019.
Full story:
AIChE SmartBrief
Chemical engineering news
Designed specifically for chemical engineers, AIChE SmartBrief is a FREE weekly email newsletter. It helps chemical engineers stay informed on the business and technology developments affecting our profession.
SUBSCRIBE